CompletedPhase 3NCT03759197
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
Studying Body integrity dysphoria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Therapeutics, Inc.
- Principal Investigator
- Tony AndrasfayTherapeutics, Inc.
- Intervention
- 188-0551 Spray(drug)
- Enrollment
- 206 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2019
Study locations (12)
- Site 06, Fort Smith, Arkansas, United States
- Site 09, Fountain Valley, California, United States
- Site 07, Fremont, California, United States
- Site 02, Aventura, Florida, United States
- Site 04, Brandon, Florida, United States
- Site 01, Largo, Florida, United States
- Site 05, North Miami Beach, Florida, United States
- Site 08, Albany, Indiana, United States
- Site 03, Plainfield, Indiana, United States
- Site 11, Louisville, Kentucky, United States
- Site 12, Metairie, Louisiana, United States
- Site 10, Fountain Inn, South Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03759197 on ClinicalTrials.govOther trials for Body integrity dysphoria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06898905Hyperfractionated Dual Equivalent Fractionated Radiation TherapyYale University
- RECRUITINGPHASE1NCT06966388Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing RadiationVirginia Commonwealth University
- RECRUITINGPHASE1, PHASE2NCT06853015Double Dose 4-AP on Functional Recovery After Spinal Cord InjuryShirley Ryan AbilityLab
- ACTIVE NOT RECRUITINGPHASE3NCT05456425A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumCloudbreak Therapeutics, LLC